Insmed Inc.'s eventful ride with Arikayce (inhaled liposomal amikacin) took an upswing with word from the FDA that the compound has achieved breakthrough designation in nontuberculous mycobacterial (NTM) lung disease, despite missing its primary endpoint in a phase II trial in that indication.
Ipierian Inc. spinout True North Therapeutics Inc. will use $22 million from its series A round to push TNT009, its lead candidate, through early stage studies in autoantibody-driven rare diseases mediated by the complement system.
Gene therapy at last is coming into its own with a new kind of "p" value, said Bluebird Bio Inc. CEO Nick Leschly. "Instead of publications, it's now about patients," he said, commenting on positive results from a phase I/II trial with a gene therapy against beta-thalassemia major – data that started followers of Bluebird speculating on whether the approach will work in sickle cell disease (SCD), too.
Fresh from a prostate cancer deal with Johnson & Johnson unit Janssen Biotech Inc. and in the midst of ushering an immunotherapy bid against pancreatic cancer through phase IIb trials, Aduro Biotech Inc. nailed down $55 million in a series C round that should see the privately held company into 2016.
Half of all multiple sclerosis (MS) patients in the nearly $16 billion (and growing) market will be taking oral drugs two years from now, and they'll cycle from one to another, just as they've done in the past with other therapies, predicted Receptos Inc. CEO Faheem Hasnain.
Bolstering its hepatitis C virus (HCV) position as patent skirmishes continue in the space, Merck & Co. Inc. snatched up Idenix Pharmaceuticals Inc. for $24.50 in cash per share, or about $3.85 billion, in a 300 percent-plus premium deal approved by the boards of both companies and set to close during the third quarter of this year.
Jitters over prospects with any candidate in Alzheimer's disease (AD) failed to deter investors from putting up to $30.8 million into Transition Therapeutics Inc., which not only has AD work ongoing but also a phase II trial in type 2 diabetes with heavyweight partner Eli Lilly and Co.
Edge Therapeutics Inc. could cut to the front of the line in aneurysmal subarachnoid hemorrhage (aSAH) therapy with its polymeric microparticle form of the calcium channel blocker nimodipine, EG-1962, advancing into the second cohort of a phase I/II trial.
This isn’t exactly “funny” – nothing about cancer is – but during the American Society of Clinical Oncology (ASCO) meeting in Chicago I couldn’t help noticing the multitude of hand-sanitizer vending devices posted around McCormick Place. They seemed … odd there. “Scrub some alcohol gel on your hands, so you don’t catch cold! Oh, cancer? Not a lot we can do about that. We’re working on it.” So they are. The number of abstracts submitted and attendees set records this year. I’m not always assigned to cover ASCO, but I’ve done my share, and 2014’s meeting seemed uncommonly active. Of...
CHICAGO – As the American Society of Clinical Oncology (ASCO) meeting entered day two, coffee-sipping attendees perked to a first-in-the-morning discussion of the phase III data with Pharmacyclics Inc.'s ibrutinib (branded Imbruvica) in relapsed chronic lymphocytic leukemia (CLL), the first time an oral drug has yielded survival improvement over standard therapy.
